Investigational drug · Phase 2
MT200605
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Ischemic Stroke.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "MT200605"
First trial start
2025
Sep 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MT200605", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Ischemic Stroke
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "MT200605" as an intervention, largest first.
- A Clinical Trial of MT200605 for the Treatment of Acute Ischemic StrokePivotal-lookingCompleted
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT07205328 · 360 participants · Start Sep 30, 2025 · Primary completion Jun 12, 2026
Drug: MT200605; MT200605 and 2 more · For: Acute Ischemic Stroke
Sites: Beijing, China
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT05948774 · 61 participants · Start Jul 11, 2023 · Primary completion Jan 22, 2024
Drug: MT200605 for Injection; MT200605 Placebo · For: Healthy
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical and first-in-human phase I trial of MT200605: A novel TrkB agonist for acute ischaemic stroke.
Li X, Zhang M, Wang B, et al. · Br J Clin Pharmacol 2026
Also in development for Acute Ischemic Stroke
- TAK-755rADAMTS13, recombinant ADAMTS13Phase 33 trials
Takeda · Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke
- SovateltideIRL-1620, PMZ-1620Phase 32 trials
Pharmazz, Inc. · Traumatic Brain Injury, Acute Ischemic Stroke, Cerebral Stroke
- JX10Phase 31 trial
Corxel Pharmaceuticals · Acute Ischemic Stroke
- SHPL-49Phase 31 trial
Shanghai Hutchison Pharmaceuticals Limited · Acute Ischemic Stroke
- LT3001Phase 23 trials
Lumosa Therapeutics Co., Ltd. · Acute Ischemic Stroke
- LT3001 DrugPhase 22 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Acute Ischemic Stroke
- B2065Phase 21 trial
Tasly Pharmaceutical Group Co., Ltd · Acute Ischemic Stroke
- BB-031DTRI-031Phase 21 trial
Basking Biosciences, Inc. · Acute Ischemic Stroke
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.